MiNK Therapeutics (NASDAQ:INKT) Trading Down 0.9% - Should You Sell?

Key Points

• MiNK Therapeutics (NASDAQ: INKT) shares fell 0.9% to $14.27, with trading volume down 39% compared to average daily levels.
• Analyst ratings for MiNK Therapeutics are mixed, with one strong buy, two buys, one hold, and one sell, along with a consensus target price of $37.50.
• The company reported a loss of ($1.06) earnings per share for the last quarter, missing consensus estimates significantly by ($0.51).

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) were down 0.9% during mid-day trading on Monday . The stock traded as low as $14.00 and last traded at $14.27. Approximately 28,693 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 46,921 shares. The stock had previously closed at $14.40.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on INKT shares. Wall Street Zen cut MiNK Therapeutics to a "strong sell" rating in a report on Saturday, August 23rd. Zacks Research cut MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday, August 18th. B. Riley upgraded MiNK Therapeutics to a "strong-buy" rating in a report on Friday, July 18th. William Blair cut MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 11th. Finally, HC Wainwright upgraded MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 target price on the stock in a report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, MiNK Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $37.50.

MiNK Therapeutics Price Performance

The stock has a market capitalization of $68.21 million, a price-to-earnings ratio of -5.24 and a beta of 0.33. The business has a fifty day moving average of $16.47 and a 200 day moving average of $11.10.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.51). On average, equities research analysts expect that MiNK Therapeutics, Inc. will post -2.75 EPS for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.